Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...

THE LAWSUIT: A class action securities lawsuit was filed against Moderna, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 18, ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Shares of Moderna Inc. MRNA shed 2.96% to $69.86 Wednesday, on what proved to be an all-around dismal trading session for the ...